Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a New Spark in Treating Oligorecurrent Prostate Cancer: Adding Systemic Treatment to Stereotactic Body Radiotherapy or Metastasectomy: Key to Long-lasting Event-free Survival?

NCT05352178 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT05352178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05352178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a New Spark in Treating Oligorecurrent Prostate Cancer: Adding Systemic Treatment to Stereotactic Body Radiotherapy or Metastasectomy: Key to Long-lasting Event-free Survival?
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Phase 3
Overall status
Recruiting
Start date
April 20, 2022
Completion date
April 25, 2032
Enrollment
873 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone sensitive prostate cancer, metastatic cancer, oligometastasis, oligometastatic disease, prostate cancer, prostate cancer metastatic, prostate cancer recurrent